Macrophage activation by ursolic and oleanolic acids during mycobacterial infection

Molecules

Volumn 20, Issue 8, 2015, Pages 14348-14364

  López García, Sonia ^a,b   Castañeda Sanchez, Jorge Ismael ^c   Jiménez Arellanes, Adelina ^d   Domínguez López, Lilia ^a   Castro Mussot, Maria Eugenia ^a   Hernández Sanchéz, Javier ^b   Luna Herrera, Julieta ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

CD36; Macrophages; Nitric oxide (NO); Oleanolic acid; Reactive oxygen species (ROS); TGR5; Transforming growth factor (TGF ); Triterpenes; Tuberculosis; Tumor necrosis factor (TNF ); Ursolic acid

Indexed keywords

NITRIC OXIDE; OLEANOLIC ACID; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA1; TRITERPENE; TUMOR NECROSIS FACTOR ALPHA; URSOLIC ACID;

ANIMAL; BIOSYNTHESIS; CELL CULTURE TECHNIQUE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MACROPHAGE; MACROPHAGE ACTIVATION; METABOLISM; MOUSE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

ANIMALS; CELL CULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MYCOBACTERIUM TUBERCULOSIS; NITRIC OXIDE; OLEANOLIC ACID; REACTIVE OXYGEN SPECIES; TRANSFORMING GROWTH FACTOR BETA1; TRITERPENES; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84941254050     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules200814348     Document Type: Article

References (54)

1. Du, H.; Wu, J.; Li, H.; Zhong, P.X.; Xu, Y.J.; Li, C.H.; Ji, K.X.; Wang, L.S. Polyphenols and triterpenes from Chaenomeles fruits: Chemical analysis and antioxidant activities assessment. Food Chem. 2013, 15, 4260-4268.
2. Muller, D.; Triebel, S.; Rudakovski, O.; Richling, E. Influence of triterpenoids present in apple peel on inflammatory gene expression associated with inflammatory bowel disease (IBD). Food Chem. 2013, 15, 339-346.
3. Jäger, S.; Trojan, H.; Kopp, T.; Laszczyk, M.N.; Scheffler, A. Pentacyclic triterpene distribution in various plants-Rich sources for a new group of multi-potent plant extracts. Molecules 2009, 14, 2016-2031.
4. Liu, J. Oleanolic acid and ursolic acid: Research perspectives. J. Ethnopharmacol. 2005, 22, 92-94.
5. Jimenez-Arellanes, A.; Meckes, M.; Torres, J.; Luna-Herrera, J. Anti-mycobacterial triterpenoids from Lantana hispida (Verbenaceae). J. Ethnopharmacol. 2007, 111, 202-205.
6. Tanachatchairatana, T.; Bremner, J.B.; Chokchaisiri, R.; Suksamrarn, A. Antimycobacterial activity of cinnamate-based esters of the triterpenes betulinic, oleanolic and ursolic acids. Chem. Pharm. Bull. 2008, 56, 194-198.
7. Moraes, T.M.; de Araújo, M.H.; Bernardes, N.R.; de Oliveira, D.B.; Lasunskaia, E.B.; Muzitano, M.F.; da Cunha M. Antimycobacterial activity and alkaloid prospection of Psychotria species (Rubiaceae) from the Brazilian Atlantic rainforest. Planta Medica 2011, 77, 964-970.
8. Fontanay, S.; Grare, M.; Mayer, J.; Finance, C.; Duval, R.E. Ursolic, oleanolic and betulinic acids: Antibacterial spectra and selectivity indexes. J. Ethnopharmacol. 2008, 120, 272-276.
9. Szakiel, A.; Ruszkowski, D.; Grudniak, A.; Kurek, A.; Wolska, K.; Doligalska, M.; Janiszowska, W. Antibacterial and antiparasitic activity of oleanolic acid and its glycosides isolated from marigold (Calendula officinalis). Planta Medica 2008, 74, 1709-1715.
10. Kong, L.; Li, S.; Liao, Q.; Zhang, Y.; Sun, R.; Zhu, X.; Zhang, Q.; Wang, J.; Wu, X.; Fang, X.; et al. Oleanolic acid and ursolic acid: Novel hepatitis C virus antivirals that inhibit NS5B activity. Antiviral Res. 2013, 98, 44-53.
11. Dufour, D.; Pichette, A.; Mshvildadze, V.; Bradette-Hébert, M.E.; Lavoie, S.; Longtin, A.; Laprise, C.; Legault, J. Antioxidant, anti-inflammatory and anticancer activities of methanolic extracts from Ledum groenlandicum Retzius. J. Ethnopharmacol. 2007, 111, 22-28.
12. Shyamal, S.; Latha, P.G.; Suja, S.R.; Shine, V.J.; Anuja, G.I.; Sini, S.; Pradeep, S.; Shika, P.; Rajasekharan, S. Hepatoprotective effect of three herbal extracts on aflatoxin B1-intoxicated rat live. Singap. Med. J. 2010, 51, 326-331.
13. Jimenez-Arellanes, A.; Meckes, M.; Alvarez, V.; Torres, J.; Parra, R. Secondary metabolites from Chamaedora tepejilote (Palmae) are active against Mycobacterium tuberculosis. Phytother. Res. 2005, 19, 320-322.
14. Jung, T.Y.; Pham, T.N.; Umeyama, A.; Shoji, N.; Hashimoto, T.; Lee, J.J.; Takei, M. Ursolic acid isolated from Uncaria rhynchophylla activates human dendritic cells via TLR2 and/or TLR4 and induces the production of IFNγ by CD4+ naive T cells. Eur. J. Pharmacol. 2010, 643, 297-303.
15. World Health Organization. Global Tuberculosis Report 2014. Available online: http://www.apps.who.int/iris/bitstream/10665/137094/1/9789241564809-eng.pdf (accessed on 6 April 2015).
16. Ananthan, S.; Faaleolea, E.R.; Goldman, R.C.; Hobrath, J.V.; Kwong, C.D.; Laughon, B.E.; Maddry, J.A.; Mehta, A.; Rasmussen, L.; Reynolds, R.C.; et al. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis 2009, 89, 334-353.
17. Jiménez-Arellanes, A.; Luna-Herrera, J.; Cornejo-Garrido, J.; López-García, S.; Castro-Mussot, M.E.; Meckes-Fischer, M.; Mata-Espinosa, D.; Marquina, B.; Torres, J.; Hernández-Pando, R. Ursolic and oleanolic acids as antimicrobial and immunomodulatory compounds for tuberculosis treatment. BMC Complement. Altern. Med. 2013, 13, 258, doi:10.1186/1472-6882-13-258.
18. Saaby, L.M.; Nielsen, C.H. Triterpene acids from rose hip powder inhibit self-antigen- And LPS-induced cytokine production and CD4+ T-cell proliferation in human mononuclear cell cultures. Phytother. Res. 2012, 26, 1142-1147.
19. Podder, B.; Jang, W.S.; Nam, K.W.; Lee, B.E.; Song, H.Y. Ursolic acid activates intracellular killing effect of macrophages during Mycobacterium tuberculosis infection. J. Microbiol. Biotechnol. 2015, 25, 738-744.
20. Rivero-Lezcano, O.M.; González-Cortés, C.; Reyes-Ruvalcaba, D.; Diez-Tascón, C. CCL20 is overexpressed in Mycobacterium tuberculosis-infected monocytes and inhibits the production of reactive oxygen species (ROS). Clin. Exp. Immunol 2010, 162, 289-297.
21. Brzezinska, M.; Szulc, I.; Brzostek, A.; Klink, M.; Kielbik, M.; Sulowska, Z.; Pawelczyk, J.; Dziadek, J. The role of 3-ketosteroid 1(2)-dehydrogenase in the pathogenicity of Mycobacterium tuberculosis. BMC Microbiol. 2013, 13, doi:10.1186/1471-2180-13-43.
22. Chakravarti, B.; Maurya, R.; Siddiqui, J.A.; Bid, H.K.; Rajendran, S.M.; Yadav, P.P.; Konwar, R. In vitro anti-breast cancer activity of ethanolic extract of Wrightiatomentosa: Role of pro-apoptotic effects of oleanolic acid and ursolic acid. J. Ethnopharmacol. 2012, 142, 72-79.
23. Liu, L.; Fu, J.; Li, T.; Cui, R.; Ling, J.; Yu, X.; Ji, H.; Zhang, Y. A novel PABA/NO-based oleanolic acid derivative induces human hepatoma cell apoptosis via a ROS/MAPK-dependent mitochondrial pathway. Eur. J. Pharmacol. 2012, 15, 1-3.
24. Tiwari, B.M.; Kannan, N.; Vemu, L.; Raghunand, T.R. The Mycobacterium tuberculosis PE proteins Rv0285 and Rv1386 modulate innate immunity and mediate bacillary survival in macrophages. PLoS ONE 2012, 7, e51686.
25. Stewart, C.R.; Stuart, L.M.; Wilkinson, K.; van Gils, J.M.; Deng, J.; Halle, A.; Rayner, K.J.; Boyer, L.; Zhong, R.; Frazier, W.A.; et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 2010, 11, 155-161.
26. Huang, Z.; Zhang, Y.; Zhao, L.; Jing, Y.; Lai, Y.; Zhang, L.; Guo, Q.; Yuan, S.; Zhang, J.; Chen, L.; et al. Synthesis and anti-human hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid. Org. Biomol. Chem. 2010, 8, 632-639.
27. Khan, N.; Gowthaman, U.; Pahari, S.; Agrewala, J.N. Manipulation of coestimulatory U molecules by intracellular pathogens: Veni, vidi, vici!! PLoS Pathogen. 2012, 8, e1002676.
28. Tomioka, H.; Tatano, Y.; Maw, W.W.; Sano, C.; Kanehiro, Y.; Shimizu, T. Characteristics of suppressor macrophages induced by mycobacterial and protozoa infections in relation to alternatively activated M2 macrophages. Clin. Dev. Immunol. 2012, 2012, doi:10.1155/2012/635451.
29. Ikeda, Y.; Murakami, A.; Ohigashi, H. Ursolic acid: An anti- And pro-inflammatory triterpenoid. Mol. Nutr. Food Res. 2008, 52, 26-42.
30. Choi, C.Y.; You, H.J.; Jeong, H.G. Nitric oxide and tumor necrosis factor-alfa production by oleanolic acid via nuclear factor kappa b activation in macrophages. Biochem. Biophys. Res. Commun. 2001, 288, 49-55.
31. Ríos, J.L. Effects of triterpenes on the immune system. J. Ethnopharmacol. 2010, 128, 1-14.
32. Szuster-Ciesielska, A.; Plewka, K.; Daniluk, J.; Kandefer-Szerszen, M. Betulin and betulinic acid attenuate ethanol-induced liver stellate cell activation by inhibiting reactive oxygen species (ROS), cytokine (TNF-α, TGF-β) production and by influencing intracellular signaling. Toxicology 2011, 27, 152-163.
33. Lugo-Villarino, G.; Vérollet, C.; Maridonneau-Parini, I.; Neyrolles, O. Macrophage polarization: Convergence point targeted by Mycobacterium tuberculosis and HIV. Front. Immunol. 2011, 2, 43, doi:10.3389/fimmu.2011.00043.
34. Ikeda, Y.; Murakami, A.; Fujimura, Y.; Tachibana, H.; Yamada, K.; Masuda, D.; Hirano, H.; Yamashita, S.; Ohigashi, H. Aggregated ursolic acid, a natural triterpenoid, induces IL-1beta release from murine peritoneal macrophages: role of CD36. J. Immunol. 2007, 178, 4854-4864.
35. Genet, C.; Strehle, A.; Schmidt, C.; Boudjelal, G.; Lobstein, A.; Schoonjans, K.; Souchet, M.; Auwerx, J.; Saladin, R.; Wagner, A. Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: Potential impact in diabetes. J. Med. Chem. 2010, 53, 178-190.
36. Wilkinson, K.; Boyd, J.D.; Glicksman, M.; Moore, K.J.; El-Khoury, J. A high content drug screen identifies ursolic acid as an inhibitor of amyloid β protein interactions with its receptor CD36. J. Biol. Chem. 2011, 286, 34914-34922.
37. Park, Y.M. CD36, a scavenger receptor implicated in atherosclerosis. Exp. Mol. Med. 2014, 46, e99, doi:10.1038/emm.2014.38.
38. Mattos, K.A.; Oliveira, V.C.; Berrêdo-Pinho, M.; Amaral, J.J.; Antunes, L.C.; Melo, R.C.; Acosta, C.C.; Moura, D.F.; Olmo, R.; Han, J.; et al. Mycobacterium leprae intracelular survival relies on colesterol accumulation in infected macrophages: A potential target for new drugs for leprosy treatment. Cell Microbiol. 2014, 16, 797-815.
39. Hawkes, M.; Li, X.; Crockett, M.; Diassiti, A.; Finney, C.; Min-Oo, G.; Liles, W.C.; Liu, J.; Kain, K.C. CD36 deficiency attenuates experimental mycobacterial infection. BMC Infect. Dis. 2010, 10, 299, doi:10.1186/1471-2334-10-299.
40. Triantafilou, M.; Gamper, F.G.; Haston, R.M.; Mouratis, M.A.; Morath, S.; Hartung, T.; Triantafilou, K. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J. Biol. Chem. 2006, 281, 31002-3111.
41. Drage, M.G.; Pecora, N.D.; Hise, A.G.; Febbraio, M.; Silverstein, R.L.; Golenbock, D.T.; Boom, W.H.; Harding, C.V. TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell Immunol. 2009, 258, 29-37.
42. Thomas, C.; Gioiello, A.; Noriega, L.; Strehle, A.; Oury, J.; Rizzo, G.; Macchiarulo, A.; Yamamoto, H.; Mataki, C.; Pruzanski, M.; et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009, 10, 167-177.
43. Duboc, H.; Taché, Y.; Hofmann, A.F. The bile acid TGR5 membrane receptor: From basic research to clinical application. Dig. Liver Dis. 2014, 46, 302-312.
44. Keitel, V.; Reinehr, R.; Gatsios, P.; Rupprecht, C.; Görg, B.; Selbach, O.; Häussinger, D.; Kubitz, R. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 2007, 45, 695-704.
45. Eggink, H.M.; Soeters, M.R.; Pols, T.W. TGR5 ligands as potential therapeutics in inflammatory diseases. Intl. J. Interferon Cytokine Mediat. Res. 2014, 6, 27-38.
46. Wang, Y.D.; Chen, W.D.; Yu, D.; Forman, B.M.; Huang, W. The G-protein coupled bile acid receptor Gpbar1 (TGR5) negatively regulates hepatic inflammatory response through antagonizing Nuclear Factor κB. Hepatology 2011, 54, 1421-1432.
47. Lou, G.; Ma, X.; Fu, X.; Meng, Z.; Zhang, W.; Wang, Y.D.; Van Ness, C.; Yu, D.; Xu, R.; Huang, W. GPBAR1/TGR5 mediates bile acid-induced cytokine expression in murine Kupffer cells. PLoS ONE 2014, 9, e93567.
48. Calmus, Y.; Poupon, R. Shaping macrophages function and innate immunity by bile acids: Mechanisms and implication in cholestatic liver diseases. Clin. Res. Hepatol. Gastroenterol. 2014, 38, 550-556.
49. Kida, T.; Tsubosaka, Y.; Hori, M.; Ozaki, H.; Murata, T. Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 1663-1669.
50. Mobraten, K.; Haugbro, T.; Karlstrom, E.; Kleiveland, C.R.; Lea, T. Activation of the bile acid receptor TGR5 enhances LPS-induced inflammatory responses in a human monocytic cell line. J. Recept. Signal Transduct. Res. 2014, 24, 1-8.
51. Forge, D.; Cappoen, D.; Laurent, J.; Stanicki, D.; Mayence, A.; Huang, T.L.; Verschaeve, L.; Huygen, K.; Van den Eynde, J.J. 1, 4-diarylpiperazines and analogs as anti-tubercular agents: Synthesis and biological evaluation. Eur. J. Med. Chem. 2012, 49, 95-101.
52. Pauli, G.F.; Case, R.J.; Inui, T.; Wang, Y.; Cho, S.; Fischer, N.H.; Franzblau, S.G. New perspectives on natural products in TB drug research. Life Sci. 2005, 78, 485-494.
53. Luna-Herrera, J.; Reddy, M.V.; Gangadharam, P.R. In-vitro and intracellular activity of rifabutin on drug-susceptible and multiple drug-resistant (MDR) tubercle bacilli. J. Antimicrob. Chemother. 1995, 36, 355-363.
54. García-Pérez, B.A.; Villagómez-Palatto, D.A.; Castañeda-Sánchez, J.I.; Coral-Vázquez, R.; Ramírez-Sánchez, I.; Ordoñez-Razo, R.M.; Luna-Herrera, J. Innate response of human endothelial cells infected with mycobacteria. Immunobiology 2011, 216, 925-935.